Relief Therapeutics Holding SA

Equities

RLF

CH1251125998

Biotechnology & Medical Research

End-of-day quote Swiss Exchange Other stock markets 18:00:00 2024-06-16 EDT			5-day change	1st Jan Change
1.17 ^CHF	-0.85%		-0.85%	-41.21%

06-03	Relief Therapeutics Holding Announces Term Expiration of Michelle Lock as Interim Chief Executive Officer	CI
06-03	Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors	CI

Relief Therapeutics Holding Announces Term Expiration of Michelle Lock as Interim Chief Executive Officer

June 03, 2024 at 01:20 am

Relief Therapeutics Holding SA announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company. Her contract was not renewed upon its expiration on May 31, 2024.

Latest news about Relief Therapeutics Holding SA

Relief Therapeutics Holding Announces Term Expiration of Michelle Lock as Interim Chief Executive Officer	06-03	CI
Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors	06-03	CI
Relief Therapeutics Restructures Management Team, Creates New Roles	05-08	MT
Relief Therapeutics Announces Executive Changes	05-08	CI
Relief Therapeutics Holding SA Announces Chief Financial Officer Changes	05-08	CI
Relief Therapeutics Holding SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Relief Therapeutics' FY23 Loss Widens; Revenue Edges Down	04-30	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	03-22	MT
Sector Update: Health Care	03-22	MT
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	03-22	MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	03-22	MT
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE	03-22	CI
Relief Therapeutics Extends CHF50 Million Share Subscription Facility with Largest Shareholder	02-28	MT
Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor	02-27	CI
Relief Therapeutics to Run Commercial Operations Via Partnership Model	12-05	MT
Relief Therapeutics CEO to Leave; Interim Successor Takes Over	11-22	MT
Relief Therapeutics Holding Sa Announces CEO Changes	11-22	CI
Relief Therapeutics Meets Outstanding ADR Requirement for Nasdaq Listing	23-10-10	MT
Relief Therapeutics Holding AG(SWX:RLF) dropped from S&P Global BMI Index	23-09-18	CI
Relief Therapeutics Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-15	CI
Relief Therapeutics Posts Wider H1 Loss; Revenue Down	23-09-15	MT
Relief Therapeutics Sells License for Urea Cycle Disorder Drug to Acer Therapeutics	23-08-31	MT
Relief Therapeutics Holding AG Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics	23-08-30	CI
Relief Therapeutics Announces Extension of Distribution Agreement for Pku Golike®? in the U.S. with Pentec Health	23-07-19	CI
Relief Therapeutics Extends US Distribution Deal with Pentec Health for PKU GOLIKE	23-07-19	MT

Chart Relief Therapeutics Holding SA

Duration

Period

More charts

Company Profile

RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Companyâs objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-06-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RELIEF THERAPEUTICS HOLDING SA	-41.21%	16.45M
MODERNA, INC.	+38.66%	52.85B
IQVIA HOLDINGS INC.	-7.81%	38.87B
LONZA GROUP AG	+35.60%	38.24B
CELLTRION, INC.	-10.77%	26.79B
ICON PUBLIC LIMITED COMPANY	+11.77%	26.16B
ALNYLAM PHARMACEUTICALS, INC.	-17.82%	19.9B
UNITED THERAPEUTICS CORPORATION	+35.09%	13.18B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
BIO-TECHNE CORPORATION	-3.05%	11.79B

Other Biotechnology & Medical Research